Peer-reviewed veterinary case report
Using liposomes and nanoparticles to improve cancer treatment in dogs
By Zabielska-Koczywąs, Katarzyna & Lechowski, Roman·Published in Molecules (Basel, Switzerland)·2017·Department of Small Animal Diseases with Clinic·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: The Use of Liposomes and Nanoparticles as Drug Delivery Systems to Improve Cancer Treatment in Dogs and Cats.
- Species:
- dog
Plain-English summary
Cancer is a leading cause of death in dogs and cats, and new treatments are being explored to improve outcomes. Researchers are looking into using liposomes and nanoparticles to deliver cancer-fighting drugs more effectively while minimizing side effects. For example, liposomal doxorubicin has shown promise for dogs with heart issues, as it is less likely to cause heart problems compared to traditional doxorubicin. Other promising treatments include nanoparticles that deliver cisplatin and paclitaxel, which may help treat various types of canine cancers like oral melanoma and anal gland adenocarcinoma.
People also search for: dog cancer treatment options · liposomal doxorubicin for dogs · nanoparticles for cat cancer · oral melanoma treatment in dogs · side effects of doxorubicin in dogs
Abstract
BACKGROUND: Cancer remains a leading cause of death in companion animals. In human medicine, liposomes and nanoparticles have been extensively investigated as drug delivery systems (DDS) for anticancer agents due to their ability to target cancerous cells and reduce the negative side effects of free cytostatic drugs. In this review, the authors discuss the results of clinical trials using liposomes and polymer-based nanoparticles as DDS to improve cancer treatment in dogs and cats, indicating which ones seem worth further evaluation. The authors then overview ongoing animal cancer clinical trials, evaluating nano-DDS registered on the American Veterinary Medical Association Animal Health Studies Database. Finally, the authors indicate the nano-drugs that require further in vivo evaluation based on the encouraging results obtained from in vitro studies. CONCLUSIONS: Liposomes have been the most investigated nano-DDS in veterinary medicine. The lack of cardiotoxicity of the commercially available liposomal doxorubicin (Doxil/Caelyx) suggests it should be used in dogs with cardiac disorders, rather than using free doxorubicin. Cisplatin-incorporated hyaluronic acid nanoparticles, nanocrystals of cisplatin, and paclitaxel are the most promising nano-drugs for potent applications in treating various canine cancers (e.g. oral melanoma, oral sarcoma, and anal gland adenocarcinoma) and their translation into the treatment of human diseases.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/29215573/